Sanjivani Paranteral Allots 5 Lakh Warrants at ₹147.39
Key highlights
- Sanjivani Paranteral allotted 5,00,000 fully convertible warrants to promoter Ashwani Khemka.
- The warrants were allotted at ₹147.39 each, representing a potential ₹7.37 crore infusion.
- BSE granted in-principle approval for the preferential issue on November 6, 2026.
- Full conversion could raise the promoter's holding to the previously stated 32.62% from 29.88%.
powered by IRIS

Sanjivani Paranteral Limited allotted 5 lakh fully convertible warrants to promoter Ashwani Khemka at ₹147.39 each, representing a potential capital infusion of ₹7.37 crore through the preferential issue disclosed on November 21, 2026. The allotment advances a proposal previously approved by the board and cleared in principle by BSE.
Know Sanjivani Paranteral inside out
Results, valuation, peers and who's buying, in one view.
What did Sanjivani Paranteral allot to its promoter?
Sanjivani Paranteral allotted 5,00,000 fully convertible warrants to Ashwani Khemka, identified in the disclosures as a promoter of the company. Each warrant is priced at ₹147.39 and is convertible into one equity share, implying a potential issue of an equal number of equity shares upon full conversion.
At the stated price, the transaction has an aggregate potential value of ₹7.3695 crore, or approximately ₹7.37 crore. The filing is significant because it records the warrant allotment stage of the preferential issue, following the earlier corporate and exchange approvals for the proposal.
The supplied filing information does not state a market-price reaction on the date of allotment. It also does not provide a revised shareholding pattern after allotment or confirm the timing of conversion into equity shares. Investors should therefore distinguish the issue of warrants from the subsequent issue and listing of shares after conversion.
How did the preferential warrant issue progress?
Sanjivani Paranteral's board had approved the proposed issue of up to 5 lakh fully convertible warrants to Ashwani Khemka on July 23, 2026. The proposal was subject to shareholder approval, and the warrants were structured to be convertible in one or more tranches within 18 months at the holder's option, according to the earlier disclosure.
BSE subsequently granted in-principle approval on November 6, 2026, which the company disclosed on November 7. The approval was issued under Regulation 28(1) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. BSE specified that its clearance was not final listing approval for the resulting securities.
The November 21 filing states that the warrants have now been allotted. Under the earlier BSE communication, the company was required to complete post-issue formalities and separately apply for listing of equity shares after allotment and conversion, while complying with the Companies Act, 2013, and SEBI's ICDR regulations.
What are the conversion and ownership implications?
The warrants are fully convertible into equity shares, with each warrant corresponding to one equity share of face value ₹10. If all 5 lakh warrants are converted, the company will issue 5 lakh additional equity shares to the promoter, subject to the applicable process and requirements.
The July disclosure said that Ashwani Khemka's stake would rise to 32.62% from 29.88% on full conversion. That earlier indication describes the potential ownership outcome if the entire warrant entitlement is converted. The November 21 filing provided in the prompt does not disclose a different ownership estimate.
For existing shareholders, conversion would increase the number of outstanding equity shares and can result in dilution of their percentage holding. The extent of that dilution depends on the company's share capital at the time of conversion and whether there are other changes in outstanding securities. The warrant allotment alone is not the same as an immediate issue of all the underlying equity shares.
Got a follow-up? Ask IRIS
Where had Sanjivani Paranteral planned to use the funds?
Sanjivani Paranteral had earlier clarified that approximately ₹5.80 crore of the proposed warrant-issue proceeds would be used for machinery expenditure and working capital in its subsidiary, SPL Infusion Private Limited. The clarification was disclosed in September 2026 in connection with the proposed 5 lakh warrant issue.
The stated uses linked the fund raise to capital expenditure and subsidiary operations. Machinery spending can support production capacity or operational assets, while working capital supports day-to-day requirements such as inventory, receivables and operating payments. The supplied November 21 allotment filing does not set out any revised allocation of proceeds.
The difference between the potential issue value of ₹7.37 crore and the approximately ₹5.80 crore use-of-funds reference should not be interpreted as a new use of proceeds without a further company disclosure. The available material only establishes that the company had previously outlined machinery and subsidiary working-capital requirements as proposed objects of the issue.
What does the allotment mean for investors and operations?
The allotment formally moves the promoter funding proposal forward after the board approval and BSE's in-principle clearance. For Sanjivani Paranteral, the potential ₹7.37 crore represents promoter-backed funding tied to a preferential warrant structure rather than a broadly offered equity issue.
For investors, the principal items to monitor are conversion of the warrants, the resulting equity-share issuance, the updated promoter holding and the company's disclosures on utilisation of funds. The prior disclosure allows conversion in one or more tranches within 18 months, so the final equity impact may depend on when and to what extent the warrants are converted.
No financial-performance metric, share-price movement or operational milestone was disclosed with the November 21 allotment information provided here. As a result, the filing supports a clear conclusion on the size, price and recipient of the warrant allotment, but not a conclusion on its immediate effect on earnings or market valuation.
Conclusion
Sanjivani Paranteral has allotted 5 lakh fully convertible warrants to promoter Ashwani Khemka at ₹147.39 each, creating a potential ₹7.37 crore infusion. The step follows the board's July approval and BSE's November in-principle approval, while full conversion could increase the promoter's holding to the previously indicated 32.62%.
The next disclosures to watch are the timing and extent of warrant conversion, issuance and listing of the underlying equity shares, and any update on deployment of funds for machinery and SPL Infusion Private Limited's working capital. The earlier terms permit conversion in one or more tranches within 18 months.


